Basilea Pharmaceutica is a Switzerland-based biopharmaceutical company, established in 2000 as a spin-out from Roche with the divestment of its anti-infective portfolio. Basilea is listed on the SIX Swiss stock exchange and is strategically focused on anti-infectives. Revenue growth will continue to be driven from its two marketed anti-infectives, Cresemba (antifungal, for invasive mould infections) and Zevtera (antibiotic, for hospital infections). Cresemba is commercialised globally through partners such as Pfizer and Astellas. In June 2022, Basilea announced positive top-line results from the Phase III ERADICATE study, investigating the use of its drug-resistant antibacterial agent, Zevtera (ceftobiprole) in the treatment of Staphylococcus aureus bacteraemia. In combination with the 2019 Phase III TARGET study in acute bacterial skin and skin structure infections, the results complete the data package for Basilea to seek FDA approval for Zevtera in both indications.
In this video, CEO David Veitch and CMO Marc Engelhardt discuss Basilea’s recent clinical milestones and strategy.